期刊文献+

葡甲胺对瑞格列奈助溶作用的研究 被引量:2

Solubilization of Meglumine on Repaglinide
下载PDF
导出
摘要 目的:研究葡甲胺对瑞格列奈的助溶机理。方法:选用助溶剂葡甲胺与瑞格列奈生成分子络合物,以增加药物溶解度,并采用差示扫描量热(DSC)法进行判断。采用HPLC-MS分析葡甲胺-瑞格列奈分子络合物的组成,并采用HPLC法考察葡甲胺与瑞格列奈不同摩尔比、葡甲胺不同浓度及不同温度对分子络合物稳定性的影响。结果:葡甲胺与瑞格列奈形成了分子络合物,瑞格列奈与葡甲胺的最佳摩尔比为1∶1。随着葡甲胺浓度增加,瑞格列奈的溶解度也随之增加。温度升高,分子络合物的稳定性降低。结论:葡甲胺对其有良好的助溶作用。 Objective: To study the solubility of repaglinide in meglumine aqueous solution. Methods: In order to increase the solubility of repaglinide, meglumine was used to react with repaglinide and obtain a molecular complex. The structure and composition of meglumine-repaglinide complex was analyzed by DSC, HPLC and HPLC-MS. Results: Meglumine and repaglinide formed a molecu- lar complex, and their best molar ratio was 1 : 1. With the concentration increase of meglumine, the solubility of repaglinide also in- creased. The stability of molecular complexes decreased with the temperature increase. Conclusion: Meglumine plays a good role in the solubilization of repaglinide.
出处 《中国药师》 CAS 2017年第1期189-192,共4页 China Pharmacist
关键词 葡甲胺 瑞格列奈 分子络合物 助溶 Meglumine Repaglinide Molecular complex Solubilization
  • 相关文献

参考文献4

二级参考文献29

  • 1刘旭霞,钮伟真.ATP敏感钾通道调控机制研究进展[J].医学研究通讯,2005,34(4):58-60. 被引量:3
  • 2肖衍宇,宋赟梅,陈志鹏,平其能.水飞蓟宾磷脂复合物的制备与大鼠生物利用度的研究[J].药学学报,2005,40(7):611-617. 被引量:27
  • 3张婷婷,徐文,胡生亮,何仲贵.水飞蓟宾在不同介质中平衡溶解度和表观油水分配系数的测定[J].中国药学杂志,2006,41(20):1569-1571. 被引量:48
  • 4韩书宏,邱健青,黄镇,陈亚想.瑞格列奈治疗2型糖尿病的临床疗效[J].中国医药导报,2007,4(06S):53-54. 被引量:15
  • 5Owens DR. Repaglinide prandial glucose regulator: a new class of oralantidiabetie drugs [J]. Diabet Med, 1999,15(4):28-36.
  • 6Christophe M,Anne LP,Renaud D. SUR,ABC proteins targeted by KATP channel openers [J]. Journal of Molecular and Cellular Cardi- ology, 2005, (38 ) : 951-957.
  • 7Hatorp V,Huang WC,Strange P. Repaglinide pharmacokinetics in healthy young adult and elderly subjects [J]. Clin Ther, 1999,21: 702-710.
  • 8Smith NF,Figg WD,Spaeboom A. Role of the liver-specifictrans- porters OATP1 BIland OATP1B3 in governing drug elimination [J]. Expert Opin Drug Metab Toxicol, 2005, ( 1 ) :429-445.
  • 9Bidstrup TB,Bjnsdottir I,Sidelmann UG,et al. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransfor- mation of the insulin secretagogue repaglinide [J]. Br J Clin Pharma- co, 2003,156 : 305-314.
  • 10Ruzilawati AB,Gan SH. CYP3A4 genetic polymorphism influences repaglinide pharmacolinetics [J]. Pharmacology, 2010,85 (6) : 357-364.

共引文献34

同被引文献13

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部